US tariff threats on Indian generic drugs face significant obstacles. These duties could increase American healthcare costs and potentially...

For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...

Revenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker sa...

Aurobindo Pharma is largely an export oriented drug maker, while it does have an India business which is business-to-business (B2B) involvi...

The analyst suggested a stoploss at Rs 475 .

The analyst suggested a stoploss at Rs 486 .

The analyst suggested a stop loss at Rs 465.

The analyst suggested a stop loss at Rs 472.

Sell Aurobindo Pharma Ltd. at a price target of Rs 584.0 and a stoploss at Rs 603 from entry point.

Buy Aurobindo Pharma Ltd. at a price target of Rs 790.0 and a stoploss at Rs 765 from entry point.

Buy Aurobindo Pharma Ltd. at a price target of Rs 705.0 and a stoploss at Rs 751 from entry point.

Buy Aurobindo Pharma at a price target of Rs 850 and a stop loss at Rs 750 from the entry point.

Buy Aurobindo Pharma at a price target of Rs 785 and a stop loss at Rs 732 from entry point.

Aurobindo Pharma has received final approval from the US health regulator USFDA for rosuvastatin calcium tablets, used in lowering choleste...

Aurobindo Pharma today reported a 4.97 per cent widening of its consolidated net loss to Rs 128.91 crore for the quarter ended June 30, 201...

After three consecutive years of loss, Aurobindo Pharma is cutting loose its bleeding Chinese pharma subsidiary Aurobindo Tongling, while s...

Hyderabad-based Aurobindo Pharma has decided to disinvest its loss-making subsidiary in China while acquiring a small manufacturing unit in...